Post-Market Study to Assess iTind Safety in Comparison to UroLift

This study compares two minimally invasive devices for treating benign prostatic hyperplasia (BPH) — an enlarged prostate that makes it difficult to urinate. The two devices are iTind (temporary implant to widen the urethra) and UroLift (permanent implants that hold the prostate lobes apart). Both are already approved, and this study compares their real-world safety and effectiveness in men 50 years and older. BPH is very common in older men and can significantly reduce quality of life. Unlike medications, these procedures provide mechanical relief and avoid the sexual side effects of some drug treatments. Both devices are inserted through the urethra without incisions. You may be eligible if... - You are a male aged 50 or older - You have been diagnosed with lower urinary tract symptoms due to an enlarged prostate - Your IPSS symptom score is 13 or higher - Your prostate volume is 75 cc or less - Your urine flow rate is between 5 and 15 mL/sec You may NOT be eligible if... - You have a history of prostate cancer or confirmed bladder cancer - You have a median lobe obstruction - You have a urinary tract infection or post-void residual volume above 250 mL - You are currently using a urinary catheter or cannot urinate naturally - You have had prior invasive prostate procedures or pelvic radiation Talk to your doctor to see if this trial is right for you.